Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Holdings Reduced by Virtu Financial LLC

Virtu Financial LLC cut its holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX - Free Report) by 67.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 4,682 shares of the pharmaceutical company's stock after selling 9,705 shares during the period. Virtu Financial LLC's holdings in Vertex Pharmaceuticals were worth $2,177,000 at the end of the most recent reporting period.

A number of other large investors also recently made changes to their positions in VRTX. Advisory Resource Group lifted its holdings in shares of Vertex Pharmaceuticals by 3.2% during the 3rd quarter. Advisory Resource Group now owns 1,970 shares of the pharmaceutical company's stock worth $916,000 after acquiring an additional 61 shares during the period. Hohimer Wealth Management LLC increased its position in Vertex Pharmaceuticals by 3.1% during the third quarter. Hohimer Wealth Management LLC now owns 2,320 shares of the pharmaceutical company's stock worth $1,079,000 after purchasing an additional 70 shares during the last quarter. Soltis Investment Advisors LLC raised its stake in Vertex Pharmaceuticals by 11.9% during the third quarter. Soltis Investment Advisors LLC now owns 778 shares of the pharmaceutical company's stock worth $362,000 after purchasing an additional 83 shares during the period. TD Private Client Wealth LLC boosted its holdings in shares of Vertex Pharmaceuticals by 34.3% in the 3rd quarter. TD Private Client Wealth LLC now owns 13,687 shares of the pharmaceutical company's stock valued at $6,366,000 after purchasing an additional 3,494 shares during the last quarter. Finally, Toronto Dominion Bank grew its stake in shares of Vertex Pharmaceuticals by 2.4% during the 3rd quarter. Toronto Dominion Bank now owns 134,202 shares of the pharmaceutical company's stock valued at $62,415,000 after buying an additional 3,096 shares during the period. Hedge funds and other institutional investors own 90.96% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Scotiabank lifted their target price on Vertex Pharmaceuticals from $480.00 to $486.00 and gave the company a "sector perform" rating in a report on Tuesday, November 5th. Canaccord Genuity Group lifted their price objective on Vertex Pharmaceuticals from $361.00 to $408.00 and gave the company a "sell" rating in a research note on Wednesday, November 6th. Raymond James reissued a "market perform" rating on shares of Vertex Pharmaceuticals in a research report on Thursday, October 10th. StockNews.com cut shares of Vertex Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a research report on Thursday, November 21st. Finally, UBS Group increased their price objective on shares of Vertex Pharmaceuticals from $562.00 to $586.00 and gave the stock a "buy" rating in a research report on Tuesday, November 5th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals has an average rating of "Moderate Buy" and a consensus price target of $506.20.

Vertex Pharmaceuticals Stock Down 0.1 %

NASDAQ VRTX traded down $0.39 on Friday, hitting $463.73. 1,097,080 shares of the stock traded hands, compared to its average volume of 1,185,713. The company has a current ratio of 2.47, a quick ratio of 2.20 and a debt-to-equity ratio of 0.01. The stock has a 50-day moving average of $473.33 and a 200 day moving average of $475.80. Vertex Pharmaceuticals Incorporated has a twelve month low of $391.01 and a twelve month high of $519.88. The company has a market capitalization of $119.42 billion, a P/E ratio of -233.23 and a beta of 0.36.

Vertex Pharmaceuticals (NASDAQ:VRTX - Get Free Report) last posted its quarterly earnings results on Monday, November 4th. The pharmaceutical company reported $4.38 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.77. The business had revenue of $2.77 billion for the quarter, compared to analyst estimates of $2.69 billion. Vertex Pharmaceuticals had a negative return on equity of 1.91% and a negative net margin of 4.52%. The business's revenue was up 11.6% compared to the same quarter last year. During the same period in the prior year, the company posted $3.67 EPS. As a group, analysts expect that Vertex Pharmaceuticals Incorporated will post -1.83 earnings per share for the current fiscal year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.